Compare Heron Therapeutics Inc (HRTX) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Philip Morris International Inc. — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Philip Morris International Inc. trades at $187.93 (market cap $300.37B). The key difference: Philip Morris International Inc. is far larger — about 3284.2× Heron Therapeutics Inc's market cap, and Philip Morris International Inc. pays a 3.05% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | PM | |
|---|---|---|
Market Cap | $91.46M | $300.37B |
Sector | Health | Consumer Staples |
52-Week High | $1.96 | $192.98 |
52-Week Low | $0.39 | $144.33 |
Enterprise Value | $189.36M | $346.86B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Philip Morris International (PM) trades at $192.98, up 1.65% today, near the analyst consensus price target of $194. The stock shows a bullish technical trend with strong moving average support. Fundamentally, the company reported robust 2025 results with revenue of $40.65 billion and net income of $11.35 billion, though recent news highlights a $500 million impairment charge and reduced profit guidance for 2026 due to cost pressures.
The outlook remains cautiously optimistic with 68% of analysts rating it a Buy, but investors face headwinds from currency volatility, rising illicit tobacco trade in Europe, and margin compression. The stock's valuation at a P/E of 27.13 appears full priced, requiring continued execution to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
